Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Kidney International Reports ; 8(3 Supplement):S443-S444, 2023.
Article in English | EMBASE | ID: covidwho-2251591

ABSTRACT

Introduction: Hospitalized COVID-19 patients are at increased risk for acute kidney injury (AKI, incidence 0.5-80%), which contributes to increased morbidity and mortality. However, the long-term effect of COVID-19 on kidney function is unclear, particularly in populations with a high prevalence of chronic kidney disease like ours. The aim was to assess the evolution, at least 6 months after hospital discharge, of kidney function in COVID-19 survivors who were hospitalized and did or did not develop AKI (KDIGO criteria). Additionally, patient survival was analyzed. Method(s): Prospective cohort of surviving patients with confirmed COVID-19 diagnosis, treated in our hospital from 08/Mar/2020 to 16/Oct/2021. From the inpatient registry, survivors were contacted by telephone;those who agreed to participate had a clinical interview and measurement of biochemical variables, including estimated glomerular filtration rate (eGFR) and albumin/creatinine ratio (ACR) in a single urine sample. Result(s): Of 585 patients hospitalized for COVID-19 and discharged alive, 121 (21%) developed AKI. So far, 166 without AKI and 34 with AKI have been included. Patient evaluations were performed at a mean (+/-SE) of 20.0+/-0.3 months, and main comparisons between groups are shown in Table 1 and Table 2.Overall mean time survival (+/-SE) was 26.1+/-0.5 months, and comparison of survival according to the development of AKI is shown in Figure. [Formula presented] [Formula presented] [Formula presented] Conclusion(s): A fifth part of surviving patients hospitalized for COVID-19 developed AKI, 73% of them recovered kidney function upon discharge. Patients who developed AKI had lower kidney function throughout the study and a higher ACR at the end of follow-up compared to those without AKI;however, this latter group displayed a slight decrease in eGFR at the end of the study compared to its baseline value. Survival of patients was significantly lower in those with AKI, and it was worse in those with higher stages. No conflict of interestCopyright © 2023

SELECTION OF CITATIONS
SEARCH DETAIL